Auna trades at depressed valuations despite a stable, integrated insurance and hospital business spanning Peru, Colombia, and Mexico. Operational setbacks in Mexico and Colombia have pressured results, but recent management actions and Q1 trends indicate stabilization and recovery potential. AUNA's leverage remains high (net debt/EBITDA 3.7x), but recent debt restructuring, improved cash generation, and reduced capex support deleveraging.
Auna S.A. (AUNA) Q1 2026 Earnings Call Transcript
Auna's Q1 2026 EPS misses expectations as margins tighten despite 18.7% revenue growth; shares fall 2.7% in after-hours trading.
Auna S.A. (AUNA) came out with quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.19 per share a year ago.
Auna S.A. (AUNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AUNA S.A. heads into May 19 Q1 results with a flat EPS outlook and 8%+ revenue growth expected, but weak signals from Mexico and mixed regional trends cloud sentiment.
Auna S.A. (AUNA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
AUNA eyes 12% EBITDA growth by 2026 as Mexico stabilizes, refinancing cuts costs, and hospital network gains boost demand across key markets.
Auna S.A. gains from Peru growth, stabilizing Mexico and Colombia cash flow focus, while Surgery Partners faces earnings cuts and headwinds.
AUNA advances oncology push in Mexico with new Oncocenter, insurer tie-ups, and rising revenues, signaling strong traction in a key growth market.
AUNA S.A. rallies as Peru delivers steady growth, Mexico shows turnaround signs, and improved liquidity and cash flow boost confidence in its outlook.
AUNA leans on risk-sharing models in Colombia, boosting revenues and cash flow while reducing exposure to government-intervened payors.